Oleg Shats
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Oleg Shats has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Whitney Goldner
Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
2 shared publications - Abbey L. Fingeret
Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska
1 shared publication - Ana G. Yuil Valdes
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA
1 shared publication - Anupam Kotwal
Division of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
1 shared publication - Benjamin J. Swanson
Department of Pathology, Microbiology, and Immunology, The University of Nebraska Medical Center, Omaha, NE 68198, USA
1 shared publication - Christopher Wichman
College of Public Health, University of Nebraska Medical Center, Omaha, NE 68198, USA
1 shared publication
Latest Publications
- Open Access
- 19 December 2025
- Published by MDPI AG in Current Oncology
- Vol. 33 (1) , 1
Factors Associated with Sleep Disruption and Fatigue in Thyroid Cancer Survivors
Thyroid cancer survivors often experience worse quality of life than other cancer survivors, with fatigue and sleep disturbance being common contributors. In this prospective cohort from the ICaRe2 cancer registry, survivors completed the Brief Fatigue Inventory (BFI) and Pittsburgh Sleep Quality Index (PSQI) at enrollment and follow-up, with univariate and multivariable analyses identifying factors associated with fatigue and sleep quality. Among 249 survivors (83% female, median age 42), 205 completed the BFI and 224 the PSQI. Most were low (57%) or intermediate (34%) risk or recurrence at diagnosis, and 74% had no structural recurrence. Poor sleep and greater fatigue were significantly associated with female sex (p = 0.0003 and 0.001), younger age at diagnosis (p = 0.02 and 0.0006), and vocal cord paralysis (p = 0.01 and 0.046). Fatigue was also higher in those with hypoparathyroidism (p = 0.04). No associations were found with recurrence risk, therapy response, thyroid hormone type, or TSH levels. Younger female survivors, particularly those with vocal cord paralysis or hypoparathyroidism, are more prone to fatigue and poor sleep, highlighting potential targets for interventions to improve quality of life.
- 19 December 2025
- Published by MDPI AG in Current Oncology
- Vol. 33 (1) , 1
Open AccessFactors Associated with Sleep Disruption and Fatigue in Thyroid Cancer Survivors
Thyroid cancer survivors often experience worse quality of life than other cancer survivors, with fatigue and sleep disturbance being common contributors. In this prospective cohort from the ICaRe2 cancer registry, survivors completed the Brief Fatigue Inventory (BFI) and Pittsburgh Sleep Quality Index (PSQI) at enrollment and follow-up, with univariate and multivariable analyses identifying factors associated with fatigue and sleep quality. Among 249 survivors (83% female, median age 42), 205 completed the BFI and 224 the PSQI. Most were low (57%) or intermediate (34%) risk or recurrence at diagnosis, and 74% had no structural recurrence. Poor sleep and greater fatigue were significantly associated with female sex (p = 0.0003 and 0.001), younger age at diagnosis (p = 0.02 and 0.0006), and vocal cord paralysis (p = 0.01 and 0.046). Fatigue was also higher in those with hypoparathyroidism (p = 0.04). No associations were found with recurrence risk, therapy response, thyroid hormone type, or TSH levels. Younger female survivors, particularly those with vocal cord paralysis or hypoparathyroidism, are more prone to fatigue and poor sleep, highlighting potential targets for interventions to improve quality of life.
- 1 August 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (8) , 999-1006
Characterization of Immune Infiltrate Along the Leading Edge of Differentiated Thyroid Cancer
While the impact of tumor-immune infiltrate has been reported on differentiated thyroid cancer behavior (DTC), the expression of immune checkpoints [programmed cell death protein 1 (PD-1) and its ligand (PD-L1)] alone has not been able to predict response to immunotherapies. We aimed to identify tumor-infiltrating immune cells and checkpoints associated with DTC. We performed multiplex immunofluorescence on de-paraffinized thyroid tissue collected at thyroidectomy from 17 adults with DTC to characterize the tumor immune microenvironment for leukocytes (CD45+), T cells (CD3+), T regulatory cells (Tregs) (CD3+FOXP3+), CD4+ T cells (CD3+CD4+), CD8+ T cells (CD3+CD8+), macrophages (CD68+), M2 macrophages (CD68+CD163+), M1 Macrophages (CD68+iNOS+) and immune checkpoints PD-1 and PD-L1. We compared the mean percentage expression of immune markers between tumor and adjacent thyroid tissue from the same patient by paired t-test and performed spatial analysis along the tumor's leading edge. Immune checkpoints PD-1 and PD-L1 showed a significant increase in expression intratumorally as compared to adjacent thyroid tissue (p<0.05). A higher trend for M2 macrophages was observed intratumorally compared to adjacent tissue. Along the leading edge, PD-L1 expression correlated negatively with CD45 and positively with CD163 intratumorally. On exploratory analysis, there was a non-significant trend for higher FOXP3 but less CD8 and iNOS expression in tumor from DTC with (n=3) versus without distant metastases (n=14). There was a non-significant trend for higher CD58 and iNOS expression in DTC with (n=7) than without thyroiditis (n=10). Higher tumoral PD-1 and PD-L1 expression indicate their role in DTC occurrence. A trend for more Tregs and M2 macrophages but less M1 macrophages intratumorally in patients with distant metastatic DTC, suggests their potential role as prognostic biomarkers. Future studies with larger sample sizes are needed to compare various clinicopathologic severities to harness tumor microenvironment for cancer prognostication and therapy.
- 1 August 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (8) , 999-1006
Characterization of Immune Infiltrate Along the Leading Edge of Differentiated Thyroid Cancer
While the impact of tumor-immune infiltrate has been reported on differentiated thyroid cancer behavior (DTC), the expression of immune checkpoints [programmed cell death protein 1 (PD-1) and its ligand (PD-L1)] alone has not been able to predict response to immunotherapies. We aimed to identify tumor-infiltrating immune cells and checkpoints associated with DTC. We performed multiplex immunofluorescence on de-paraffinized thyroid tissue collected at thyroidectomy from 17 adults with DTC to characterize the tumor immune microenvironment for leukocytes (CD45+), T cells (CD3+), T regulatory cells (Tregs) (CD3+FOXP3+), CD4+ T cells (CD3+CD4+), CD8+ T cells (CD3+CD8+), macrophages (CD68+), M2 macrophages (CD68+CD163+), M1 Macrophages (CD68+iNOS+) and immune checkpoints PD-1 and PD-L1. We compared the mean percentage expression of immune markers between tumor and adjacent thyroid tissue from the same patient by paired t-test and performed spatial analysis along the tumor's leading edge. Immune checkpoints PD-1 and PD-L1 showed a significant increase in expression intratumorally as compared to adjacent thyroid tissue (p<0.05). A higher trend for M2 macrophages was observed intratumorally compared to adjacent tissue. Along the leading edge, PD-L1 expression correlated negatively with CD45 and positively with CD163 intratumorally. On exploratory analysis, there was a non-significant trend for higher FOXP3 but less CD8 and iNOS expression in tumor from DTC with (n=3) versus without distant metastases (n=14). There was a non-significant trend for higher CD58 and iNOS expression in DTC with (n=7) than without thyroiditis (n=10). Higher tumoral PD-1 and PD-L1 expression indicate their role in DTC occurrence. A trend for more Tregs and M2 macrophages but less M1 macrophages intratumorally in patients with distant metastatic DTC, suggests their potential role as prognostic biomarkers. Future studies with larger sample sizes are needed to compare various clinicopathologic severities to harness tumor microenvironment for cancer prognostication and therapy.